NEW YORK (GenomeWeb News) – Lumera’s life sciences subsidiary Plexera today said it has signed an option agreement for protein array technology from Harvard University spinout Auguron Biosciences.
The company said it will use Auguron’s Nucleic Acid Programmable Protein Array (NAPPA), which was developed at the Harvard Institute of Proteomics, to generate functional proteins on high density microchips from surface printed DNA.
The deal builds on a longstanding collaboration between Lumera and the Harvard Institute of Proteomics related to the NAPPA technology. Auguron was formed early last year to commercialize technology developed in the institute.
The option agreement grants Plexera access for one year and includes the potential for another one-year extension. During that period, Plexera said it will test and develop the NAPPA technology as a potential content source for its Plexera Kx Array platform in collaboration with Auguron and with other partners, which the company did not name.
The agreement also gives Plexera the option to negotiate an exclusive license for NAPPA.
"By printing DNA and expressing proteins in-situ, NAPPA skips the expense, time, yield and activity consuming steps associated with conventional printed protein arrays,” Auguron CEO Jim Richey said in a statement.
Financial terms of the license were not disclosed.